SCHEMBL23630435

SCHEMBL23630435

Sc1nc(S)nc(Nc2ccccc2Cl)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.67
IGF1R P08069 3/20 0.49
KMT2A Q03164 4/20 0.47
MAPT P10636 3/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
RAD52 P43351 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
AURKA O14965 2/20 0.42
FLT3 P36888 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30202205 1.00 TSHR (0.67) TSHRIGF1RKMT2AMAPTKDM4E
Dyrene SCHEMBL133054 0.80 TSHR (1.00) TSHRIGF1RKMT2AMAPTKDM4E
Dyrene SCHEMBL6750152 0.80 TSHR (1.00) TSHRIGF1RKMT2AMAPTKDM4E
Dyrene SCHEMBL29364667 0.80 TSHR (1.00) TSHRIGF1RKMT2AMAPTKDM4E
Dyrene SCHEMBL1903290 0.80 TSHR (1.00) TSHRIGF1RKMT2AMAPTKDM4E
Dyrene SCHEMBL8166670 0.80 TSHR (1.00) TSHRIGF1RKMT2AMAPTKDM4E
Dyrene SCHEMBL13280 0.80 TSHR (1.00) TSHRIGF1RKMT2AMAPTKDM4E
Dyrene SCHEMBL7154524 0.79 TSHR (0.89) TSHRIGF1RKMT2AMAPTKDM4E
Dyrene SCHEMBL8881784 0.78 TSHR (0.96) TSHRIGF1RKMT2AMAPTKDM4E
Dyrene SCHEMBL827164 0.78 TSHR (0.96) TSHRIGF1RKMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230101743-A1 SUBSTITUTED TRIAZINE COMPOUNDS AND USES THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT 2023-03-30 US claimed
WO-2021141984-A1 SUBSTITUTED TRIAZINE COMPOUNDS AND USES THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2021-07-15 WO claimed
US-20230101743-A1 SUBSTITUTED TRIAZINE COMPOUNDS AND USES THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT 2023-03-30 US disclosed
WO-2021141984-A1 SUBSTITUTED TRIAZINE COMPOUNDS AND USES THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2021-07-15 WO disclosed
WO-2021141984-A1 SUBSTITUTED TRIAZINE COMPOUNDS AND USES THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2021-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230101743-A1 SUBSTITUTED TRIAZINE COMPOUNDS AND USES THEREOF PCSK9, SLC10A1, CYP3A5 TSHR 976/4885IGF1R 3314/4885KMT2A 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.